Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections

被引:29
|
作者
Patel, Ursula C. [1 ]
McKissic, Erin L. [2 ]
Kasper, Douglas [3 ]
Lentino, Joseph R. [3 ]
Pachucki, Constance T. [3 ]
Lee, Todd [4 ]
Lopansri, Bert K. [3 ]
机构
[1] Edward Hines Jr VA Hosp, Dept Pharm 119, Hines, IL 60141 USA
[2] Edward Hines Jr VA Med Ctr, Dept Pharm, Hines, IL USA
[3] Edward Hines Jr VA Med Ctr, Med Serv, Sect Infect Dis, Hines, IL USA
[4] Edward Hines Jr VA Med Ctr, Dept Res, Hines, IL USA
关键词
Bacteremia; Ceftriaxone; MSSA; S; aureus; United States; Veterans; PARENTERAL ANTIMICROBIAL THERAPY; PROTEIN-BINDING; BACTEREMIA; IMPACT;
D O I
10.1007/s11096-014-9999-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Standard of care therapy (SOCT) for the treatment of methicillin susceptible staphylococcal aureus (MSSA) infections requires multiple daily infusions. Despite questionable efficacy due to high protein binding, ceftriaxone (CTX) is frequently used for treatment of MSSA at Hines VA Hospital. Objective The objective of this study was to determine clinical and microbiological outcomes in patients with MSSA bacteremia treated with CTX compared to SOCT. Setting This retrospective study was conducted at the Edward Hines, Jr. VA Hospital which is a comprehensive health care center serving the veteran population of the greater metropolitan Chicago and northwest Indiana regions and is institutionally affiliated with the Loyola University Medical Center. The Hines VA provides medical care to over 56,000 veterans and operates approximately 500 hospital beds, including acute care and nursing home beds. Method We conducted a retrospective cohort study of patients with MSSA bacteremia treated at Hines VA Hospital between January 2000 and September 2009. Patients who received either SOCT or CTX for > 50 % of the treatment course and for the appropriate duration were included. Patients who were on multiple antibiotics concurrently or who received < 14 days of therapy were excluded. Main outcome measure The primary outcome of this study is to compare clinical outcomes of patients with MSSA bacteremia who were treated with CTX compared to those who received standard of care agents. Results Ninety-three patients with MSSA bacteremia were included in the analysis. Fifty-one were treated with SOCT and 42 with CTX. There were no differences in microbiological cure between SOCT (94.1 %) and CTX (95.2 %) (p = 0.812). Clinical cure was similar between groups (74.5 % for SOCT, 83.3 % for CTX) (p = 0.303). CTX was used more often to treat Staphylococcus aureus bacteremia associated with osteomyelitis whereas endocarditis and central line associated infections were treated more frequently with SOCT (p = 0.01). More patients treated with CTX were managed in the ambulatory setting (64 vs. 24 %; p = < 0.001). There was a trend toward a longer hospital stay with SOCT. Conclusion Clinical outcomes for MSSA bacteremia did not differ significantly between patients treated with CTX and SOCT. Findings suggest that CTX may be an alternative for outpatient management of MSSA bacteremia.
引用
收藏
页码:1282 / 1289
页数:8
相关论文
共 50 条
  • [1] Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections
    Ursula C. Patel
    Erin L. McKissic
    Douglas Kasper
    Joseph R. Lentino
    Constance T. Pachucki
    Todd Lee
    Bert K. Lopansri
    International Journal of Clinical Pharmacy, 2014, 36 : 1282 - 1289
  • [2] Therapy of infections due to methicillin susceptible Staphylococcus aureus (MSSA)
    Besnier, JM
    Bastides, F
    Choutet, P
    MEDECINE ET MALADIES INFECTIEUSES, 1997, 27 : 225 - 240
  • [3] Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?
    Stefano Di Bella
    Milo Gatti
    Luigi Principe
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 917 - 918
  • [4] Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?
    Di Bella, Stefano
    Gatti, Milo
    Principe, Luigi
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (07) : 917 - 918
  • [5] Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infections Due to Methicillin-Susceptible Staphylococcus aureus: A Systematic Review and Meta-Analysis
    Alsowaida, Yazed Saleh
    Benitez, Gregorio
    Bin Saleh, Khalid
    Almangour, Thamer A.
    Shehadeh, Fadi
    Mylonakis, Eleftherios
    ANTIBIOTICS-BASEL, 2022, 11 (03):
  • [6] Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections-A Single-Center Observational Study
    Hamad, Yasir
    Connor, Lee
    Bailey, Thomas C.
    George, Ige A.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [7] Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections
    Wasielewski, Anthony S.
    Casapao, Anthony M.
    Jankowski, Christopher A.
    Isache, Carmen L.
    Ravi, Malleswari
    Coyne, Ashlan J. Kunz
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (11)
  • [8] Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections: A Noninferiority Retrospective Cohort Study
    Ganguly, Anisha
    de la Flor, Carolina
    Alvarez, Kristin
    Brown, L. Steven
    Mang, Norman S.
    Smartt, Jillian
    King, Helen
    Perl, Trish M.
    Filizola, Hector
    Bhavan, Kavita P.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (04) : 425 - 431
  • [9] Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review
    Kamfose, Musaiwale M.
    Muriithi, Francis G.
    Knight, Thomas
    Lasserson, Daniel
    Hayward, Gail
    ANTIBIOTICS-BASEL, 2020, 9 (02):
  • [10] A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections
    Miller, Matthew A.
    Fish, Douglas N.
    Barber, Gerard R.
    Barron, Michelle A.
    Goolsby, Tiffany A.
    Moine, Pierre
    Mueller, Scott W.
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (02) : 321 - 327